newcleo Inaugurates Advanced Nuclear Fuel Engineering and Testing Center in France, Furthering the Industrial Deployment of its MOX Fuel Program.
Seven test facilities are operational in a non-nuclear environment, with further installations under development.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
newcleo (NWCL) inaugurated its FASTER fuel engineering, testing and training center in Chusclan, France, representing an investment of around €10 million. The non-nuclear center supports development and qualification of manufacturing processes for MOX fuel, a mixture of uranium and plutonium oxides. Seven test facilities are operational, with further installations under development. newcleo expects the center to help reduce development risks before deployment in licensed manufacturing facilities.
The company has proposed a MOX fuel fabrication facility in France’s Aube department. In July 2026, French nuclear regulator ASNR issued an overall satisfactory evaluation of its proposed safety options, ahead of a planned construction license application. FASTER also benefits from Bonifait Pesage’s expertise; newcleo’s acquisition of that company is expected to close in Q4 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointASNR’s July 2026 evaluation found the proposed French fuel facility’s safety options overall satisfactory.
- Minor pointFASTER opened, adding a dedicated non-nuclear center for fuel-process engineering, testing and training.
- Minor pointSeven test facilities are operational, with further installations under development.
- Minor point. Forward-looking: it has not happened yet and may not happen.Proposed Aube fuel facility would manufacture MOX fuel for newcleo’s future European reactors.
- Minor point. Forward-looking: it has not happened yet and may not happen.U.S. licensing strategy is planned to incorporate ASNR feedback and recommendations during pre-licensing engagement.
Negative
- Moderate pointBonifait Pesage acquisition remains pending, with closing expected in Q4 2026.
- Minor pointAround €10 million investment represents the cost of establishing FASTER.
- Minor pointFrench fuel facility remains proposed, ahead of a planned construction license application.
Details
Market move: NWCL -7.74% vs previous close. MOX fuel center opening
On Oct 14, the day this news came out, the latest delayed price for NWCL is 7.74% below the previous close. Our momentum scanner has recorded 6 alerts for this stock so far that day. The latest delayed price is $6.32.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Center investment
- €10 million
- FASTER engineering and testing center
- Operating test facilities
- 7 facilities
- At FASTER
Historical Context
-
French regulators gave a satisfactory evaluation of proposed MOX facility safety options.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
mox fuel technical
lead-cooled fast reactors technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The
Seven test facilities are operating at the site, covering key stages of the fuel manufacturing process, from powder dosing and pellet pressing to fuel pin assembly and quality inspection.
By enabling the validation and optimization of manufacturing processes ahead of industrial deployment, FASTER represents a key milestone in de-risking newcleo’s advanced MOX fuel program and supports the development of the Company’s planned fuel manufacturing facilities.
PARIS, Oct. 14, 2026 (GLOBE NEWSWIRE) -- newcleo plc (“newcleo” or the “Company”) (NASDAQ: NWCL), a pioneer in advanced modular reactor (“AMR”) technology and nuclear fuel manufacturing, today inaugurated FASTER (Fuel process Assembly Storage Training and Enhanced Reality), its advanced nuclear fuel engineering, testing and training center located in Chusclan, in the Occitanie region of southern France.
Representing an investment of around
Similar to the Lead-cooled Fast Reactor Development and Qualification program developed by newcleo at the ENEA Brasimone Research Center, the facilities installed at FASTER will support the de-risking and continuous improvement of newcleo’s MOX fuel manufacturing technology.
Stefano Buono, Founder and CEO of newcleo, said: “FASTER is an important milestone in the industrial execution of our fuel strategy. By providing a dedicated environment to develop, test and qualify technologies before their deployment in licensed facilities, FASTER significantly de-risks our future MOX manufacturing program and accelerates our path towards industrialization in France and the United States. The center is a testament to our development model: highly skilled teams, real equipment and industrial partners transforming research and engineering into the facilities we intend to build. By developing our fuel program from within the established French nuclear industry, we are building capabilities to enable a closed nuclear fuel cycle and deploy the next generation of nuclear energy globally.”
Located near the Marcoule nuclear site, FASTER offers a dedicated, non-nuclear environment in which to develop, test and qualify technologies and manufacturing processes ahead of their future deployment in MOX fuel facilities.
The center is designed around a practical “test and learn” approach, bringing engineering and physical testing closer together. Concepts developed by newcleo’s teams are translated into prototypes and test mock-ups at FASTER, tested under representative conditions and progressively refined, helping accelerate their path towards industrial deployment.
Seven test facilities are already operational at FASTER, with further installations under development. These facilities address different stages and challenges of MOX fuel manufacturing, including powder dosing optimization, glovebox ergonomics, pellet handling, fuel pin assembly and decontamination, pellet inspection and helium filling.
Located in the heart of one of France’s key nuclear supply-chain regions, FASTER draws on expertise from across the country’s industrial and nuclear sectors. It also benefits from the specialist capabilities of newcleo’s subsidiary S.R.S. Servizi di Ricerche e Sviluppo and French nuclear-grade scales and precision weighting equipment manufacturer Bonifait Pesage, whose acquisition by newcleo is expected to close in Q4 2026.
newcleo aims to fabricate MOX nuclear fuel, a proven nuclear fuel manufactured from a mixture of uranium and plutonium oxides that has been used in commercial reactors for decades, to power its Lead-cooled Fast Reactors (LFRs) and other potential third party off-takers. When used in fast reactors, like newcleo’s LFRs, MOX enables the multi-recycling of nuclear fuel in what is known as a “closed fuel cycle”. This circular approach to nuclear fuel can extract more energy from the same amount of natural uranium compared to traditional once-through fuel cycles in thermal reactors, while at the same time significantly reducing the volume and radioactivity of nuclear waste.
newcleo has proposed the deployment of an advanced MOX fuel fabrication facility in France in the Aube department, near Nogent-sur-Seine, to manufacture fuel for its future European reactors. The project reached an important regulatory milestone in July 2026, when the French Nuclear Safety and Radiation Protection Authority (Autorité de sûreté nucléaire et de radioprotection – “ASNR”) issued an overall satisfactory evaluation for the proposed safety options, offering practical feedback to continue developing the facility’s safety features ahead of a planned construction license application in France.
As newcleo furthers its pre-licensing engagement with the U.S. Nuclear Regulatory Commission, the Company plans to adopt the ASNR feedback and recommendations to also strengthen and streamline its licensing strategy for the U.S. market.
About newcleo
newcleo is an innovative nuclear technology company developing advanced modular reactors and nuclear fuel designed to deliver clean, safe and sustainable energy at competitive costs. newcleo's technology combines lead-cooled fast reactors with fuel manufactured from recycled nuclear materials, with the aim of providing abundant and reliable electricity and heat to industrial users while enabling the closure of the nuclear fuel cycle. newcleo brings together more than 900 highly skilled employees across Europe and the United States, spanning reactor and fuel design, engineering, and manufacturing. Through a vertically integrated supply chain and a growing network of strategic partnerships, newcleo is working to turn proven scientific and engineering solutions into deployable nuclear energy assets. For more information visit. For more information visit www.newcleo.com
For media enquiries
newcleo press office
media@newcleo.com
European media enquiries
newcleo@brunswickgroup.com
For investors
newcleo@icrinc.com
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the U.S. federal securities laws. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding the completed business combination between NewHold Investment Corp III and newcleo; the anticipated benefits of the transaction; expected trading of the combined company’s securities on Nasdaq; the completion of investments from certain institutional investors; the expected amount of gross proceeds from any investments or other financing arrangements; the anticipated use of proceeds from such investments or financing arrangements; newcleo's development and commercialization of its lead-cooled fast reactor technology, mixed-oxide fuel capabilities and related products and services; the expected timing, cost, performance and benefits of newcleo's demonstration projects, fuel facilities, reactor deployments and licensing activities; newcleo's ability to execute its business strategy, develop its technology, obtain required regulatory approvals, permits and licenses, enter into commercial arrangements, achieve its market opportunity and positioning and support the growth of advanced nuclear energy; newcleo's expectations regarding strategic partnerships, customer demand, project pipeline, revenue streams, capital expenditures and financing needs; and other statements regarding management's intentions, beliefs, or expectations with respect to newcleo's future performance, are forward-looking statements. Forward-looking statements are often identified by the use of words such as "anticipate," "believe," "continue," "could," "develop," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "will," "would," and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on newcleo's current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. You should carefully consider the foregoing factors and the other risks and uncertainties described in other documents filed from time to time by newcleo with the U.S. Securities and Exchange Commission. Additional risks and uncertainties not currently known or that are currently deemed immaterial may also cause actual results to differ materially from those expressed or implied by such forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and newcleo does not assume any obligation or intend to update or revise these forward-looking statements, each of which is made only as of the date of this press release.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is newcleo’s FASTER center and how much was invested?
FASTER is newcleo’s non-nuclear fuel engineering, testing and training center in Chusclan, France, representing an investment of around €10 million. It provides an environment to develop, test and qualify technologies and manufacturing processes before deployment in MOX fuel facilities.
What regulatory milestone has newcleo’s proposed French MOX fuel facility reached?
In July 2026, ASNR issued an overall satisfactory evaluation of the proposed facility’s safety options. The evaluation provided practical feedback for further development of its safety features ahead of a planned construction license application in France.
How does newcleo plan to use French regulatory feedback for U.S. licensing?
newcleo plans to adopt ASNR feedback and recommendations to strengthen and streamline its U.S. licensing strategy. This work accompanies the company’s pre-licensing engagement with the U.S. Nuclear Regulatory Commission.